Biotech Values

[DewDiligence]

MNTA – You underestimate the potential of the generic-Copaxone program in #msg-26892883, IMO. Copaxone is currently selling at an annual rate of $1.7B, of which $1.1B is in the US (#msg-26740147).

Even in a worst-case scenario—if Copaxone were to lose 50% of its volume to newer and better MS drugs in the next half decade—the remaining sales would be an extremely attractive target for a company who can own the only generic on the market.

Moreover, if a generic Copaxone is approved, it will be fully interchangeable with the brand, obviating the need for any selling and marketing expenses.

As for the US Copaxone patent, I think it’s obvious that Sandoz has a plan to get around it.